Salix Pharmaceuticals (SLXP) 105.18 $SLXP
Technical Summary on Pharma Stocks -- Research on Salix Pharma, Nektar Therapeutics, Corcept Therapeutics, and Jazz Pharma
PR Newswire - Mon May 12, 11:30AM CDT
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The gains were broad based as six out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Nektar Therapeutics (NASDAQ: NKTR), Corcept Therapeutics Inc. (NASDAQ: CORT) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on SLXP, NKTR, CORT and JAZZ can be downloaded upon signing up at:
Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 09, 12:41PM CDT
Salix's (SLXP) first quarter 2014 earnings of 92 cents per share were far above the Zacks Consensus Estimate of 42 cents and the year-ago earnings of 53 cents per share.
Look for Shares of Salix Pharmaceuticals to Potentially Rebound after Yesterday's 4.55% Sell Off
Comtex SmarTrend(R) - Thu May 08, 4:51PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $105.26 to a high of $111.72. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $107.28 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Salix Pharmaceuticals Reports 1Q2014 Results
Business Wire - Thu May 08, 3:02PM CDT
--1Q14 EBITDA Increases 114% to $149 million
Nasdaq Erases 1% Gain; Priceline Struggles At 200-Day Line
at Investor's Business Daily - Thu May 08, 2:07PM CDT
The Nasdaq erased a 1% gain Thursday and was mostly unchanged with less than two hours to go in the session. The S&P 500 was also unchanged, while the Dow Jones industrial average gained 0.3%. Volume on the NYSE was tracking about 8% lower than...
Stocks Hold Solid Gains; WhiteWave Surges On Earnings
at Investor's Business Daily - Thu May 08, 12:34PM CDT
Major averages were firmly in positive territory just past the midway point of Thursday's trading. The Nasdaq fell off session highs but still rose 0.5%. The Dow Jones industrial average also gained 0.5% while the S&P 500 added 0.4%. Volume on the...
Nasdaq Leads Market Rally But Oil And Gas Producers Lag
at Investor's Business Daily - Thu May 08, 11:09AM CDT
Major averages rallied and were near session highs in late morning trading Thursday as investors pored over another avalanche of earnings reports. About two hours into the session, the Nasdaq rose 0.9% while the S&P 500 and Dow Jones industrial...
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Modest Losses For Stocks But EOG, Anadarko Pace Oil Rally
at Investor's Business Daily - Tue May 06, 12:28PM CDT
Buyers were in short supply Tuesday but declines were minimal in the major averages as the market remained in a holding pattern. A little more than halfway through the session, the Nasdaq and Dow Jones industrial average each fell 0.5% while the...
Salix Pharmaceuticals to Present at Two Investment Conferences in May
Business Wire - Tue May 06, 6:02AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during May 2014. Information regarding these conferences is provided below:
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2014
Business Wire - Mon May 05, 6:00AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to the investigation of one of the Company's products are scheduled to take place during Digestive Disease Week DDW2014(R). DDW2014(R) is being held in Chicago, IL, Saturday, May 3 - Tuesday, May 6, 2014.
Investing Shortcut Can Get You Up To Speed Quickly
at Investor's Business Daily - Fri May 02, 4:18PM CDT
Following the stock market can be tough if your job demands all of your time during market hours. Is there a shortcut that can get you up to speed quickly? While shortcuts aren't ideal, one way to find good stock ideas fast is IBD's Stocks On The...
PharmaPoint Report 2014: Ulcerative Colitis - Current and Future Players
M2 - Fri May 02, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4v75g/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Current and Future Players" report to their offering. PharmaPoint: Ulcerative Colitis - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Ulcerative Colitis Market. The report identifies and analyses the key companies shaping and driving the global Ulcerative Colitis market. The report provides insight into the competitive Ulcerative Colitis landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Ulcerative Colitis - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Ulcerative Colitis sector through market impact analysis, future market scenario and company analysis Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/w4...harmapoint
Transport, Drug Stocks Act Well Despite Market Woes
at Investor's Business Daily - Thu May 01, 5:42PM CDT
Transportation and drug stocks are holding up relatively well during the market's correction, with several in buying range after strong breakouts. Old Dominion Freight Lines (ODFL) cleared a 57.58 base-on-base buy point April 24 in heavy volume. It's...
RedHill Biopharma Reports Results for the First Quarter of 2014
GlobeNewswire - Wed Apr 30, 10:00AM CDT
Key financial highlights include:
Can Expedia (EXPE) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 6:30PM CDT
Expedia Inc. (EXPE) is set to report first-quarter 2014 results on May 1. Last quarter, the company posted 6.6% positive surprise. Let's see how things are shaping up for this announcement.
Forest Labs Beats Easily on 4Q Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 11:10AM CDT
Forest Labs (FRX) also announced its intention to acquire Furiex which will expand its gastrointestinal franchise.
Questcor Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:40AM CDT
Questcor Pharmaceuticals reported first quarter 2014 earnings per share of $1.24, up from the year-ago earnings of $0.85 per share but missed the Zacks Consensus Estimate of $1.71.
Forest Labs to Buy Furiex for $1.1B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:00AM CDT
In a bid to strengthen its gastrointestinal (GI) portfolio, Forest Labs (FRX) inked a deal to acquire Furiex Pharmaceuticals (FURX).
Flamel Technologies (FLML) in Focus: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:37AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Technical Summary on Pharma Stocks -- Research on Salix Pharma, Nektar Therapeutics, Corcept Therapeutics, and Jazz Pharma
PR Newswire - Mon May 12, 11:30AM CDT
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The gains were broad based as six out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Nektar Therapeutics (NASDAQ: NKTR), Corcept Therapeutics Inc. (NASDAQ: CORT) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on SLXP, NKTR, CORT and JAZZ can be downloaded upon signing up at:
Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 09, 12:41PM CDT
Salix's (SLXP) first quarter 2014 earnings of 92 cents per share were far above the Zacks Consensus Estimate of 42 cents and the year-ago earnings of 53 cents per share.
Look for Shares of Salix Pharmaceuticals to Potentially Rebound after Yesterday's 4.55% Sell Off
Comtex SmarTrend(R) - Thu May 08, 4:51PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $105.26 to a high of $111.72. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $107.28 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Salix Pharmaceuticals Reports 1Q2014 Results
Business Wire - Thu May 08, 3:02PM CDT
--1Q14 EBITDA Increases 114% to $149 million
Nasdaq Erases 1% Gain; Priceline Struggles At 200-Day Line
at Investor's Business Daily - Thu May 08, 2:07PM CDT
The Nasdaq erased a 1% gain Thursday and was mostly unchanged with less than two hours to go in the session. The S&P 500 was also unchanged, while the Dow Jones industrial average gained 0.3%. Volume on the NYSE was tracking about 8% lower than...
Stocks Hold Solid Gains; WhiteWave Surges On Earnings
at Investor's Business Daily - Thu May 08, 12:34PM CDT
Major averages were firmly in positive territory just past the midway point of Thursday's trading. The Nasdaq fell off session highs but still rose 0.5%. The Dow Jones industrial average also gained 0.5% while the S&P 500 added 0.4%. Volume on the...
Nasdaq Leads Market Rally But Oil And Gas Producers Lag
at Investor's Business Daily - Thu May 08, 11:09AM CDT
Major averages rallied and were near session highs in late morning trading Thursday as investors pored over another avalanche of earnings reports. About two hours into the session, the Nasdaq rose 0.9% while the S&P 500 and Dow Jones industrial...
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Modest Losses For Stocks But EOG, Anadarko Pace Oil Rally
at Investor's Business Daily - Tue May 06, 12:28PM CDT
Buyers were in short supply Tuesday but declines were minimal in the major averages as the market remained in a holding pattern. A little more than halfway through the session, the Nasdaq and Dow Jones industrial average each fell 0.5% while the...
Salix Pharmaceuticals to Present at Two Investment Conferences in May
Business Wire - Tue May 06, 6:02AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during May 2014. Information regarding these conferences is provided below:
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2014
Business Wire - Mon May 05, 6:00AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to the investigation of one of the Company's products are scheduled to take place during Digestive Disease Week DDW2014(R). DDW2014(R) is being held in Chicago, IL, Saturday, May 3 - Tuesday, May 6, 2014.
Investing Shortcut Can Get You Up To Speed Quickly
at Investor's Business Daily - Fri May 02, 4:18PM CDT
Following the stock market can be tough if your job demands all of your time during market hours. Is there a shortcut that can get you up to speed quickly? While shortcuts aren't ideal, one way to find good stock ideas fast is IBD's Stocks On The...
PharmaPoint Report 2014: Ulcerative Colitis - Current and Future Players
M2 - Fri May 02, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4v75g/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Current and Future Players" report to their offering. PharmaPoint: Ulcerative Colitis - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Ulcerative Colitis Market. The report identifies and analyses the key companies shaping and driving the global Ulcerative Colitis market. The report provides insight into the competitive Ulcerative Colitis landscape, including new companies entering the market. Scope - Investigation of current and future market competition for Ulcerative Colitis - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Ulcerative Colitis sector through market impact analysis, future market scenario and company analysis Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/w4...harmapoint
Transport, Drug Stocks Act Well Despite Market Woes
at Investor's Business Daily - Thu May 01, 5:42PM CDT
Transportation and drug stocks are holding up relatively well during the market's correction, with several in buying range after strong breakouts. Old Dominion Freight Lines (ODFL) cleared a 57.58 base-on-base buy point April 24 in heavy volume. It's...
RedHill Biopharma Reports Results for the First Quarter of 2014
GlobeNewswire - Wed Apr 30, 10:00AM CDT
Key financial highlights include:
Can Expedia (EXPE) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 6:30PM CDT
Expedia Inc. (EXPE) is set to report first-quarter 2014 results on May 1. Last quarter, the company posted 6.6% positive surprise. Let's see how things are shaping up for this announcement.
Forest Labs Beats Easily on 4Q Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 11:10AM CDT
Forest Labs (FRX) also announced its intention to acquire Furiex which will expand its gastrointestinal franchise.
Questcor Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:40AM CDT
Questcor Pharmaceuticals reported first quarter 2014 earnings per share of $1.24, up from the year-ago earnings of $0.85 per share but missed the Zacks Consensus Estimate of $1.71.
Forest Labs to Buy Furiex for $1.1B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:00AM CDT
In a bid to strengthen its gastrointestinal (GI) portfolio, Forest Labs (FRX) inked a deal to acquire Furiex Pharmaceuticals (FURX).
Flamel Technologies (FLML) in Focus: Stock Surges 11.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:37AM CDT
Flamel Technologies SA (FLML) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
